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ABSTRACT
Background: We have recently shown that early postmenopausal but not premenopausal asthmatic women
treated with inhaled corticosteroids demonstrate reduced bone mineral density(BMD)and decreased serum in-
tact osteocalcin levels. Thus, the development of therapeutic approaches would be desirable for the prevention
and intervention of BMD reduction in postmenopausal asthmatic women receiving inhaled corticosteroids．
Methods: This study was aimed at examining the effects of etidronate disodium on BMD in 20 postmeno-
pausal asthmatic women with reduced BMD of the lumbar spine(T score ; −1.5 or less). These patients had
been managed by inhaled beclomethasone dipropionate or inhaled fluticasone propionate, without regular use
of oral or parentheral corticosteroids. They were given a 200 mgday oral dose of etidronate disodium for 14
days every three months. BMD of the lumbar spine was determined at baseline and at 1 or 3 years after the
treatment．
Results: The baseline BMD was 0.692±0.018(SE)gcm2(T score, −3.0±0.8). The BMD significantly increased
by 5.2±2.0% at 1 year(P=0.022)and by 7.3±2.9% at 3 years(P=0.037)after the treatment.
Conclusions: Intermittent cyclical treatment with ethidronate improves reduced BMD in postmenopausal
asthmatic women on inhaled corticosteroid therapy．
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INTRODUCTION
Inhaled corticosteroids are now the mainstay for
long-term treatment of bronchial asthma.1 Although
systemic use of corticosteroids is a well-known risk
for osteoporosis, it has remained undetermined as to
whether long-term use of inhaled corticosteroids can
cause osteoporosis.2,3 Inconsistent conclusions drawn
from previous studies on the effects of inhaled corti-
costeroids on bone are probably due to the differ-
ences in clinical characteristics of the study patients
with regard to sex, age, menstrual status , and co-
administration of systemic corticosteroids.4-10 In this
regard, we previously analyzed bone mineral density
(BMD)and biochemical markers of bone metabolism
in pre- and early post-menopausal asthmatic women
treated with inhaled beclomethasone propionate but
without oral or parentheral administration of corti-
costeroids for at least 1 year. Our results showed that
inhaled corticosteroids have unfavorable effects on
bone in postmenopausal but not in premenopausal
asthmatics.11 Therefore, it can be postlated that thera-
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Table 1 Characteristics of etidronate-treated postmenopausal asthmatic women
20Number
(60―78)69.7±1.1Age
(4―34)19.2±1.7Years after menopause (year)
11/9/0Asthma status (step 2/3/4)*
(118―1034)647±52Dose of inhaled corticosteroids (μg/day)**
(0.531―0.795)0.692±0.018BMD of lumbar spine (L2-L4) (g/cm2)
(－4.3―－2.0)－3.0±0.8BMD of lumbar spine (L2-L4) (T-score)
Data are means±SE or n. Ranges are shown in parenthesis. *Asthma status is according to NHLBI/WHO (1995) classification. **Dose 
of inhaled corticosteroids is expressed as that of beclomethasone. Dose of fluticasone is multiplied by 2 for the conversion.
Fig. 1　Changes of lumbar spinal BMD in 20 postmeno-
pausal asthmatic patients receiving inhaled corticosteroids 
before and after treatment with intermitent cyclical etidro-
nate. Data represent mean ±SE.
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peutic approaches would be necessary for the preven-
tion and intervention of BMD reduction in inhaled
corticosteroids-treated postmenopausal patients．
Bisphosphonates are potent inhibitors of bone re-
sorption mediated by osteoclasts both in vitro and in
vivo. Several treatments using these agents as well as
ovarian hormones have been shown effective in pre-
venting bone loss and vertebral fracture in patients
who were given systemic corticosteroids . 12-16 How-
ever, strategies for the prevention of bone loss in pa-
tients with use of inhaled corticosteroids are not yet
confirmed. In the present study , we evaluated the
therapeutic benefit of intermittent cyclical therapy of
etidronate for reduction of bone loss in postmeno-
pausal asthmatic patients receiving inhaled corti-
costeroids.
METHODS
EXPERIMENTAL SUBJECTS
Among 784 Japanese female patients who were diag-
nosed with bronchial asthma at the Miyatake Asthma
Clinic by the American Thoracic Society criteria,17 we
randomly recruited 20 postmenopausal women satis-
fying the following admission criteria : no continuous
use of oral corticosteroid therapy ; no histry of estro-
gens or progestins use ; no endocrine, metabolic or
renal disorders ; no lumbar spinal deformities ; no
bone fractures ; and a lumbar spine BMD T score of
−1.5 or less . None of the women had a history of
smoking. All patients were fully ambulatory and their
ADLs were normal. They were managed by inhaled
beclomethasone dipropionate or inhaled fluticasone
propionate, and disodium cromoglycate, β-stimulants,
andor theophylline. All the patients properly used a
metered-dose inhaler with a spacer(Volumatic ; Glaxo
SmithKline , Middlesex , UK , or Inspire-Ease ;
Schering-Plough, Kenilworth, NJ). In 12 patients who
had been taking alfacalcidol(1.0 μgday), the admini-
stration continued throughout the study period. They
were managed by the same physician(A. M.)in the
outpatient clinic every 2 or 4 weeks.
STUDY DESIGN
All patients in the study were treated with intermit-
tent cyclical etidronate ( Sumitomo Pharmaceutical ,
Osaka, Japan) . They were administered etidronate
disodium 200 mgday for 14 days for every 3-month
period. During the study period, some of the patients
received oral or parenteral administration of corti-
costeroids for short time for the treatment of asthma
attack . BMD was measured at the lumbar spine
(L2-L4) level using the dual-energy X-ray absorpti-
ometry(DXA)technique at baseline and at 1, 2 or 3
years after the administration of etidronate. The pro-
tocol in this study was approved by the regional ethi-
cal committee, and all the patients provided informed
consent．
BMD MEASUREMENTS
BMD was measured with DXA scans(Hologic QDR-
2000, Waltham, MA) . The measurement was per-
formed by the same technician who was not informed
about the clinical status of the patient．
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STATISTICAL ANALYSIS
All results are shown as means±SE. Data were com-
pared using analysis of variance and by paired t -test.
Differences associated with P<0.05 were considered
statistically significant.
RESULTS
Clinical characteristics of the twenty postmenopausal
women with bronchial asthma at entry of the study
are shown in Table 1. Age of the study patients was
69.7±1.1 years and 19.2±1.7 years from after the time
menopause. The dose of inhaled corticosteroids was
647±52 μgday of beclomethasone. All patients were
diagnosed as step 2 or step 3 asthma statuses, accord-
ing to NHLBIWHO(1995)classification. Their base-
line lumber spine(L2-L4)BMD was 0.692±0.018 gcm
2(T score −3.0±0.8 ; −4.3～−2.0). Twelve patients(60%)
had BMD T score of −2.5 or less, which was opera-
tionally defined as osteoporosis by the World Health
Organization . 18 Changes in the lumbar BMD are
shown in Figure 1. At 1 year after etidronate treat-
ment, BMD significantly increased by 5.2±2.0%(n=11,
P=0.022). After 3 years of treatment, there were sig-
nificant increases by 7.3±2.9% from baseline(n=12, P=
0.037). In patients with alfacalcidol BMD changes at 1
year and at 3 years were 6.1±3.1%(n=7)and 11.3±4.3%
(n=7), whereas those were 3.6±1.7%(n=4)and 1.7±1.2%
(n=5)in patients without alfacalcidol. There was no
statistically significant difference between the both
groups. None of the study patients had esophageal or
gastrointestinal complaints during the study period.
Laboratory examinations revealed no abnormalities
of hepatic or renal function.
DISCUSSION
There has been some controversy concerning the ef-
fects of inhaled corticosteroids on bone density and
fractures in asthmatic patients . 4-10 A recent study19
showed a negative correlation between total cumula-
tive dose of inhaled corticosteroids and BMD in asth-
matic men and women aged 20―40 years . A large
scale of study using a data base of patients of averag-
ing age 45 years of age20 has shown that users of in-
haled corticosteroid have an increased risk of bone
fracture but this excess risk may be more related to
the underlying respiratory disease than to inhaled
corticosteroids. Reduced respiratory function is also
shown to be associated with spinal deformity 21 as
well as low BMD.22 Thus, many variables, such as
age, sex, menstrual status, respiratory function and
use of systemic corticosteroids, should be considered
in the analysis of the involvement of inhaled corti-
costeroids in osteoporosis and the effects of various
drugs on its prevention. We have recently shown that
inhaled corticosteroids reduce BMD in early post-
menopausal but not in premenopausal asthmatic
women.11 From these observations, we thought that
it is important to find therapeutic modalities for treat-
ing bone loss in postmenopausal asthmatic patients
receiving inhaled corticosteroids.
In this investigation, intermittent cyclical admini-
stration of etidronate was found to increase BMD in
20 postmenopausal asthmatic women. A statistically
significant increment was evident at 1 year as well as
3 years after the treatment. Control patients without
etidronate treatment were not evaluated in this study.
However , it is known that postmenopausal elderly
women show no significant increase in BMD. Thus,
the results of the present study indicate the efficacy
of the intermittent cyclical etidronate treatment for in-
creasing BMD in postmenopausal asthmatic women
receiving inhaled corticosteroids . The increases in
BMD(5.2±2.0% at 1 year and 7.3±2.9% at 3 years)cor-
responded to those obtained by effective treatment
with antiresorptive drugs in postmenopausal women
(5―10% in 2 years), which were associated with a de-
crease in the fracture rate of approximately 50%.23
It has been recently shown that the other bisphos-
phonate alendronate treatments increased BMD in
patients on inhaled corticosteroid therapy.24 This re-
cent study included patients with bronchial asthma as
well as those with chronic obstructive airway dis-
eases. About half of the study patients were premeno-
pausal and some patients were on oral corticoster-
oids. In addition, only 10% had BMD T scores less
than −2.5. By contrast, in the present investigation,
we focused on postmenopausal asthmatic women
without continuous use of oral corticosteroids in
whom BMD T scores were −1.5 or less, which is the
threshold for treatment by National Osteoporosis
Foundation criteria.25 Average BMD T score was −3.0
(range ; −4.3 to −2.0). Sixty % of the study patients
had a BMD T score −2.5 or less and thus they were
diagnosed with osteoporosis based on the definition
by a working group of the World Health Organiza-
tion.18 Therefore, our study is the first to demonstrate
the effectiveness of the use of bisphosphonate for re-
ducing BMD in postmenopausal asthmatic women
who were treated with inhaled corticosteroids but no
continuous use of systemic corticosteroids.
Twelve patients had been taking alfacalcidol before
entry of this study and continued to receive it
throughout the study period, whereas the other 8 pa-
tients did not. BMD changes had a tendency to be
slightly higher in patients taking alfacalcidol , but
there was no statistically significant difference of
BMD changes between both groups. It remains to be
determined whether alfacalcidol has an additive effect
on the action of bisphosphonates to increase BMD in
postmenopausal osteoporosis . Thus , further study
will be also needed to clarify the effects of co-
administration of cyclical etidronate and alfacalcidol
on bone metabolism in asthmatic women with in-
haled corticosteroids．
Our previous study11 has revealed that serum in-
tact osteocalcin concentration was depressed in post-
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menopausal asthmatics receiving corticosteroids
compared with postmenopausal control subjects. By
contrast, urinary pyridinoline and deoxypyridinoline
concentrations did not differ between the postmeno-
pausal asthmatics and the postmenopausal control
subjects . These results indicate that inhaled corti-
costeroids cause reduced bone formation rather than
increased bone resorption. Therefore, approaches to
increase bone formation would ideally be desirable
for the treatment of bone loss in postmenopausal
asthmatic women. Since the main mechanism of ac-
tion of etidronate is interference with osteoclast func-
tion and inhibition of bone resorption, the reason for
its effectiveness on the bone loss in inhaled
corticosteroids-treated postmenopausal asthmatic
women seems unclear. In this study, we did not de-
termine biochemical markers of bone metabolism be-
fore and after the etidronate treatment. It has been
shown that etidronate prevented bone loss in patients
with systemic corticosteroid therapy in whom it de-
creased levels of the bone resorption marker urinary
pyridinium as well as of the bone formation marker
osteocalcin . 15 Taken all together , the inhibitory ef-
fects of etidronate on bone resorption in postmeno-
pausal state may surpass the inhibition of bone forma-
tion by inhaled corticosteroids.
In conclusion, we found that intermittent cyclical
etidronate therapy was effective in the treatment of
bone loss in postmenopausal asthmatic patients re-
ceiving inhaled corticosteroids. Since wide use of in-
haled corticosteroids is now associated with de-
creased mortality of asthmatic patients,26 the preven-
tion of osteoporosis and osteoporotic fracture will be
important in the consideration of health problems in
asthmatic women treated with inhaled corticoster-
oids.
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